Insider Selling: Neumora Therapeutics, Inc. (NASDAQ:NMRA) Insider Sells $363,606.28 in Stock

Neumora Therapeutics, Inc. (NASDAQ:NMRA) insider Robert A. Lenz sold 30,788 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $11.81, for a total value of $363,606.28. Following the completion of the transaction, the insider now directly owns 339,205 shares in the company, valued at approximately $4,006,011.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Neumora Therapeutics Trading Up 1.5 %

Neumora Therapeutics stock opened at $12.92 on Friday. The firm’s 50 day moving average price is $11.74 and its 200-day moving average price is $11.41. Neumora Therapeutics, Inc. has a 1 year low of $8.33 and a 1 year high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.37). On average, equities analysts forecast that Neumora Therapeutics, Inc. will post -1.51 EPS for the current year.

Institutional Investors Weigh In On Neumora Therapeutics

Several large investors have recently made changes to their positions in the company. Artal Group S.A. boosted its stake in Neumora Therapeutics by 14.5% during the first quarter. Artal Group S.A. now owns 2,924,052 shares of the company’s stock valued at $40,206,000 after buying an additional 371,350 shares during the last quarter. Avidity Partners Management LP raised its holdings in shares of Neumora Therapeutics by 10.6% during the 4th quarter. Avidity Partners Management LP now owns 1,990,632 shares of the company’s stock worth $33,940,000 after acquiring an additional 190,632 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in shares of Neumora Therapeutics during the 1st quarter worth approximately $10,354,000. Callan Capital LLC boosted its position in shares of Neumora Therapeutics by 222.6% during the 2nd quarter. Callan Capital LLC now owns 661,194 shares of the company’s stock valued at $6,500,000 after acquiring an additional 456,207 shares during the last quarter. Finally, Baker BROS. Advisors LP purchased a new position in shares of Neumora Therapeutics in the first quarter valued at $8,715,000. 47.65% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on NMRA shares. Needham & Company LLC reissued a “buy” rating and issued a $23.00 target price on shares of Neumora Therapeutics in a report on Thursday, September 12th. Royal Bank of Canada restated an “outperform” rating and set a $29.00 price objective on shares of Neumora Therapeutics in a research report on Wednesday, September 4th. Finally, Mizuho began coverage on shares of Neumora Therapeutics in a research note on Monday, July 8th. They set an “outperform” rating and a $20.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Neumora Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $22.11.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.